Our retrospective research assessed the efficiency and basic safety of irinotecan as well as raltitrexed in esophageal squamous cell cancers (ESCC) sufferers who had been previously treated with multiple systemic therapies. Further research are had a need to determine the perfect dose of both medications. = 0.088, Desk ?Desk3).3). The PFS and Operating-system were also… Continue reading Our retrospective research assessed the efficiency and basic safety of irinotecan as well as raltitrexed in esophageal squamous cell cancers (ESCC) sufferers who had been previously treated with multiple systemic therapies